Metal ion dyshomeostasis represents a fundamental pathological mechanism in neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and Huntington's disease (HD)[1][2]. The brain's delicate balance of metal ions—particularly iron, copper, zinc, and manganese—is disrupted in these disorders, leading to oxidative stress, protein aggregation, mitochondrial dysfunction, and neuronal death. Understanding metal homeostasis in the brain provides critical insights into disease mechanisms and therapeutic opportunities.
The brain requires precise regulation of metal ions for normal neurological function. Iron is essential for oxygen transport, mitochondrial function, and neurotransmitter synthesis. Copper serves as a cofactor for cytochrome c oxidase and antioxidant enzymes. Zinc plays roles in synaptic transmission and protein structure. Manganese is required for mitochondrial enzymes and neurotransmitter synthesis. When this balance is disrupted—whether through genetic factors, aging, or environmental exposure—the consequences for neuronal health can be devastating[3].
Iron is the most abundant metal in the brain and is essential for numerous neuronal functions[4]. The brain has specialized mechanisms for iron uptake, transport, and storage:
Iron accumulation is a prominent feature of AD brain pathology[5]:
The relationship between iron and Aβ is bidirectional: iron promotes Aβ aggregation, while Aβ can sequester iron, creating a complex pathogenic loop[6].
Iron dysregulation is particularly pronounced in PD[7]:
The selective vulnerability of substantia nigra neurons may relate to their high iron content and neuromelanin binding capacity[8].
Iron dysregulation in ALS includes[9]:
Copper is essential for numerous enzymatic reactions in the brain[10]:
Copper dysregulation contributes to both AD and PD pathogenesis[11]:
Zinc plays crucial roles in synaptic transmission and plasticity[12]:
Zinc dysregulation contributes to neurodegeneration through[13]:
Excess manganese exposure causes manganism, a PD-like syndrome[14]:
Manganese may contribute to sporadic PD[15]:
The relationship between Aβ and metals is complex[16]:
α-Synuclein interacts with multiple metals[17]:
Tau pathology is influenced by metal ions[18]:
Metal chelation has been explored as a therapeutic strategy[19]:
| Compound | Metal Targeted | Status |
|---|---|---|
| Deferoxamine | Iron | Clinical trials for AD |
| Deferasirox | Iron | Investigational |
| Clioquinol | Copper/Zinc | Clinical trials |
| PBT2 | Copper/Zinc | Clinical trials |
MPACs differ from chelators by preserving normal metal homeostasis[20]:
Other approaches include[21]:
The Fenton reaction is a key mechanism of metal-mediated oxidative stress[22]:
Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻
Cu⁺ + H₂O₂ → Cu²⁺ + •OH + OH⁻
The hydroxyl radical (•OH) is the most reactive ROS and damages lipids, proteins, and DNA.
Fenton chemistry contributes to neurodegeneration through[23]:
Brain metal levels can be assessed through[24]:
Peripheral markers include[25]:
Metal ion dyshomeostasis intersects with multiple pathways:
Metal ion dyshomeostasis is a unifying feature of neurodegenerative diseases, linking protein aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation. While chelation therapy has shown limited success, emerging approaches targeting specific metals and their interactions with disease proteins offer promise. The development of better metal imaging and blood biomarkers will aid in diagnosis and monitoring of therapeutic response.
Brett & Bush, Metal ions and neurodegeneration (2023). 2023. ↩︎
Kaur et al. Metal dyshomeostasis in neurodegenerative diseases (2024). 2024. ↩︎
Crichton et al. Brain iron homeostasis (2024). 2024. ↩︎
Ward et al. Iron metabolism in the brain (2023). 2023. ↩︎
Pochedeenko et al. Iron in Alzheimer's disease (2024). 2024. ↩︎
Liu et al. Iron and amyloid-beta interaction (2023). 2023. ↩︎
Zecca et al. Iron in Parkinson's disease (2024). 2024. ↩︎
Dexter et al. Neuromelanin and iron in PD (2023). 2023. ↩︎
Connor et al. Iron in ALS (2024). 2024. ↩︎
Sanchez et al. Copper in brain function (2023). 2023. ↩︎
Barnham & Bush, Copper and zinc in neurodegeneration (2024). 2024. ↩︎
Frederickson et al. Zinc in synaptic function (2023). 2023. ↩︎
Smart et al. Zinc dysregulation in AD (2024). 2024. ↩︎
Santner & Finkbeiner, Metals and alpha-synuclein (2024). 2024. ↩︎
Lovell et al. Tau and metals (2023). 2023. ↩︎
Devos et al. Iron chelation in neurodegeneration (2024). 2024. ↩︎
O'Neill, Therapeutic approaches to metal dyshomeostasis (2024). 2024. ↩︎
Jomova & Valko, Fenton chemistry in neurodegeneration (2023). 2023. ↩︎
Haupt et al. Imaging brain metals (2024). 2024. ↩︎
Ahmadi et al. Blood biomarkers of metal status (2024). 2024. ↩︎